Application-Dependent Early-Phase Stability of Autologous Fibrin Glue in Endoscopic Transsphenoidal Surgery.
Kohei Suzuki; Yoshiteru Nakano; Ayako Yamaguchi; Masahiro Inoue; Junkoh Yamamoto
World neurosurgery, Jun. 2026, Reviewed

Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long-Term Multicenter Observational Study.
Takafumi Aritomi; Koshiro Sonomoto; Shingo Nakayamada; Hiroaki Tanaka; Atsushi Nagayasu; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Naoaki Ohkubo; Yasuyuki Todoroki; Yurie Satoh-Kanda; Masanobu Ueno; Ryuichiro Kanda; Yuya Fujita; Masashi Funada; Hidenori Sakai; Satsuki Matsunaga; Hiroaki Tanaka; Masayuki Shinojima; Hiroki Kawamura; Kazuki Takahashi; Miyabi Ando; Kazuki Haru; Yusuke Miyazaki; Kentaro Hanami; Masao Nawata; Shunsuke Fukuyo; Keisuke Nakatsuka; Mikiko Tokunaga; Kazuyoshi Saito; Yoshiya Tanaka
Arthritis & rheumatology (Hoboken, N.J.), Mar. 2026, Reviewed

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.
Atsushi Nagayasu; Yusuke Miyazaki; Koshiro Sonomoto; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Hiroaki Tanaka; Yasuyuki Todoroki; Masanobu Ueno; Takafumi Aritomi; Yuya Fujita; Hidenori Sakai; Katsunori Suzuki; Shingo Nakayamada; Yoshiya Tanaka
Rheumatology and therapy, Aug. 2025, Reviewed

Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry.
Hiroki Kobayashi; Yusuke Miyazaki; Shingo Nakayamada; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Yoshino Inoue; Yasuyuki Todoroki; Hiroko Miyata; Hiroaki Tanaka; Yoshihisa Fujino; Shintaro Hirata; Yoshiya Tanaka
Rheumatology (Oxford, England), May 2025, Reviewed

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry.
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
Rheumatology (Oxford, England), Apr. 2025, Reviewed

Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Hidenori Sakai; Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Kentaro Hanami; Shunsuke Fukuyo; Ayako Yamaguchi; Ippei Miyagawa; Masanobu Ueno; Hiroaki Tanaka; Yasuyuki Todoroki; Naoaki Ohkubo; Masashi Funada; Satsuki Matsunaga; Yoshiya Tanaka
Rheumatology (Oxford, England), Apr. 2025, Reviewed

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Ryuichiro Kanda; Yusuke Miyazaki; Shingo Nakayamada; Shunsuke Fukuyo; Satoshi Kubo; Ippei Miyagawa; Ayako Yamaguchi; Yurie Satoh-Kanda; Naoaki Ohkubo; Yasuyuki Todoroki; Hiroaki Tanaka; Masanobu Ueno; Atsushi Nagayasu; Yuya Fujita; Takafumi Aritomi; Katsuhide Kusaka; Hidenori Sakai; Satsuki Matsunaga; Hirotsugu Nohara; Yoshiya Tanaka
Rheumatology and therapy, Apr. 2025, Reviewed

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.
Yusuke Miyazaki; Shingo Nakayamada; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yurie Satoh-Kanda; Yasuyuki Todoroki; Yoshino Inoue; Masanobu Ueno; Yoshiya Tanaka
RMD open, Jan. 2025

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.
Yusuke Miyazaki; Masashi Funada; Shingo Nakayamada; Koshiro Sonomoto; Hiroaki Tanaka; Kentaro Hanami; Shunsuke Fukuyo; Satoshi Kubo; Ayako Yamaguchi; Ippei Miyagawa; Yasuyuki Todoroki; Masanobu Ueno; Yoshiya Tanaka
Rheumatology (Oxford, England), Sep. 2024

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Koshiro Sonomoto; Shingo Nakayamada; Yoshihisa Fujino; Hiroko Miyata; Satoshi Kubo; Yuya Fujita; Yoshino Inoue; Satsuki Matsunaga; Shigeru Iwata; Kentaro Hanami; Yasuyuki Todoroki; Hiroko Yoshinari-Korekoda; Akio Kawabe; Ayako Yamaguchi; Masanobu Ueno; Yurie Satoh-Kanda; Ryuichiro Kanda; Masashi Funada; Naoaki Ohkubo; Katsuhide Kusaka; Shumpei Kosaka; Atsushi Nagayasu; Shunsuke Fukuyo; Masao Nawata; Yusuke Miyazaki; Mikiko Tokunaga; Kenichi Tanaka; Yosuke Okada; Yoshiya Tanaka
Rheumatology (Oxford, England), Aug. 2024

Selection of treatment regimens based on shared decision making after sustained remission in patients with rheumatoid arthritis,-The two-year results of the FREE-J study.
山口絢子; 田中良哉
月刊リウマチ科, 2023, Not reviewed
Lead

Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Yoshiya Tanaka; Ayako Yamaguchi; Toshiaki Miyamoto; Kazuhide Tanimura; Hideyuki Iwai; Yuko Kaneko; Tsutomu Takeuchi; Koichi Amano; Naoki Iwamoto; Atsushi Kawakami; Miho Murakami; Norihiro Nishimoto; Tatsuya Atsumi; Takayuki Sumida; Koichiro Ohmura; Tsuneyo Mimori; Hisashi Yamanaka; Keishi Fujio; Yoshihisa Fujino; Kazuyoshi Saito; Kazuhisa Nakano; Shintaro Hirata; Shingo Nakayamada
Rheumatology (Oxford, England), Nov. 2022, Reviewed
Corresponding

DMARD de-escalation in patients with rheumatoid arthritis.
山口絢子; 田中良哉
月刊リウマチ科, 2022, Not reviewed
Lead

Erythrocyte sedimentation rate and CRP
山口絢子; 田中良哉
日本臨床, 2022, Not reviewed
Lead

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Yusuke Miyazaki; Kazuhisa Nakano; Shingo Nakayamada; Satoshi Kubo; Shigeru Iwata; Kentaro Hanami; Shunsuke Fukuyo; Ippei Miyagawa; Ayako Yamaguchi; Akio Kawabe; Kazuyoshi Saito; Yoshiya Tanaka
Arthritis research & therapy, Jun. 2021

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Ayako Yamaguchi; Shintaro Hirata; Satoshi Kubo; Shunsuke Fukuyo; Kentaro Hanami; Kazuhisa Nakano; Shingo Nakayamada; Kazuyoshi Saito; Yoshiya Tanaka
Modern rheumatology, Sep. 2020, Reviewed
Lead

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.
Takuya Hirai; Keigo Ikeda; Maki Fujishiro; Hiroshi Tsushima; Kunihiro Hayakawa; Satoshi Suzuki; Ayako Yamaguchi; Kazuhisa Nozawa; Shinji Morimoto; Yoshinari Takasaki; Hideoki Ogawa; Kenji Takamori; Naoto Tamura; Iwao Sekigawa
Clinical rheumatology, Jan. 2017

A re-evaluation of anti-NA-14 antibodies in patients with primary Sjögren's syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14.
Kaori Uomori; Kazuhisa Nozawa; Keigo Ikeda; Kentaro Doe; Yusuke Yamada; Ayako Yamaguchi; Maki Fujishiro; Mikiko Kawasaki; Shinji Morimoto; Kenji Takamori; Iwao Sekigawa; Edward K L Chan; Yoshinari Takasaki
Autoimmunity, Aug. 2016

CC motif chemokine ligand 13 is associated with rheumatoid arthritis pathogenesis.
Ayako Yamaguchi; Kazuhisa Nozawa; Maki Fujishiro; Mikiko Kawasaki; Fujihiko Suzuki; Kenji Takamori; Hideoki Ogawa; Yoshinari Takasaki; Iwao Sekigawa
Modern rheumatology, Sep. 2013, Reviewed
Lead

Inhibition of connective tissue growth factor ameliorates disease in a murine model of rheumatoid arthritis.
Kazuhisa Nozawa; Maki Fujishiro; Mikiko Kawasaki; Ayako Yamaguchi; Keigo Ikeda; Shinji Morimoto; Kazuhisa Iwabuchi; Mitsuaki Yanagida; Shouzo Ichinose; Megumi Morioka; Hideoki Ogawa; Kenji Takamori; Yoshinari Takasaki; Iwao Sekigawa
Arthritis and rheumatism, Jun. 2013

Estrogen inhibits apoptosis and promotes CC motif chemokine ligand 13 expression on synovial fibroblasts in rheumatoid arthritis.
Ayako Yamaguchi; Kazuhisa Nozawa; Maki Fujishiro; Mikiko Kawasaki; Kenji Takamori; Hideoki Ogawa; Iwao Sekigawa; Yoshinari Takasaki
Immunopharmacology and immunotoxicology, Oct. 2012, Reviewed
Lead

Regenerating gene (REG) 1 alpha promotes pannus progression in patients with rheumatoid arthritis.
Maki Fujishiro; Kazuhisa Nozawa; Mikiko Kawasaki; Ayako Yamaguchi; Kazuhisa Iwabuchi; Mitsuaki Yanagida; Fujihiko Suzuki; Keiji Miyazawa; Hirokazu Fukui; Kazuo Kaneko; Hideoki Ogawa; Kenji Takamori; Yoshinari Takasaki; Iwao Sekigawa
Modern rheumatology, Apr. 2012

A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus.
Iwao Sekigawa; Maki Fujishiro; Ayako Yamaguchi; Mikiko Kawasaki; Akihiro Inui; Kazuhisa Nozawa; Yoshinari Takasaki; Kennji Takamori; Hideoki Ogawa
Clinical and experimental rheumatology, 2010

Fluctuations in the gene expression of peripheral blood mononuclear cells between the active and inactive phases of systemic lupus erythematosus.
Mikiko Kawasaki; Maki Fujishiro; Ayako Yamaguchi; Kazuhisa Nozawa; Hiroshi Kaneko; Yoshinari Takasaki; Kenji Takamori; Hideoki Ogawa; Iwao Sekigawa
Clinical and experimental rheumatology, 2010

FREE-J studyにおける患者とのshared decision makingによるRA寛解時の治療選択
山口 絢子, 田中 良哉
リウマチ科, Oct. 2023, Reviewed, No invitation
Lead

【関節リウマチの治療の現状と問題点】治療薬剤の減量と休薬
山口絢子, 田中良哉
リウマチ科, Apr. 2022, Reviewed, No invitation
Lead

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
Miyazaki Yusuke, Nakano Kazuhisa, Nakayamada Shingo, Kubo Satoshi, Iwata Shigeru, Hanami Kentaro, Fukuyo Shunsuke, Miyagawa Ippei, Yamaguchi Ayako, Kawabe Akio, Saito Kazuyoshi, Tanaka Yoshiya
Arthritis research & therapy, Jun. 2021, Reviewed, No invitation

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Yamaguchi Ayako, Hirata Shintaro, Kubo Satoshi, Fukuyo Shunsuke, Hanami Kentaro, Nakano Kazuhisa, Nakayamada Shingo, Saito Kazuyoshi, Tanaka Yoshiya
Modern rheumatology, Jan. 2020, Reviewed, No invitation
Lead

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.
Miyazaki Yusuke, Nakayamada Shingo, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Miyagawa Ippei, Satoh-Kanda Yurie, Todoroki Yasuyuki, Inoue Yoshino, Ueno Masanobu, Tanaka Yoshiya
RMD open, Jan. 2025, Reviewed, No invitation

Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Sakai Hidenori, Miyazaki Yusuke, Nakayamada Shingo, Kubo Satoshi, Hanami Kentaro, Fukuyo Shunsuke, Yamaguchi Ayako, Miyagawa Ippei, Ueno Masanobu, Tanaka Hiroaki, Todoroki Yasuyuki, Ohkubo Naoaki, Funada Masashi, Matsunaga Satsuki, Tanaka Yoshiya
Rheumatology (Oxford, England), Sep. 2024, Reviewed, No invitation

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST study.
Miyazaki Yusuke, Nakayamada Shingo, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Todoroki Yasuyuki, Inoue Yoshino, Ueno Masanobu, Tanaka Yoshiya
Rheumatology (Oxford, England), Jun. 2024, Reviewed, No invitation

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Sonomoto Koshiro, Nakayamada Shingo, Fujino Yoshihisa, Miyata Hiroko, Kubo Satoshi, Fujita Yuya, Inoue Yoshino, Matsunaga Satsuki, Iwata Shigeru, Hanami Kentaro, Todoroki Yasuyuki, Yoshinari-Korekoda Hiroko, Kawabe Akio, Yamaguchi Ayako, Ueno Masanobu, Satoh-Kanda Yurie, Kanda Ryuichiro, Funada Masashi, Ohkubo Naoaki, Kusaka Katsuhide, Kosaka Shumpei, Nagayasu Atsushi, Fukuyo Shunsuke, Nawata Masao, Miyazaki Yusuke, Tokunaga Mikiko, Tanaka Kenichi, Okada Yosuke, Tanaka Yoshiya
Rheumatology (Oxford, England), Nov. 2023, Reviewed, No invitation

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.
Miyazaki Yusuke, Funada Masashi, Nakayamada Shingo, Sonomoto Koshiro, Tanaka Hiroaki, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Miyagawa Ippei, Todoroki Yasuyuki, Ueno Masanobu, Tanaka Yoshiya
Rheumatology (Oxford, England), Sep. 2024, Reviewed, No invitation

Predictors of the effectiveness to first-line CTLA4-Ig in patients with rheumatoid arthritis: the FIRST registry.
Kobayashi Hiroki, Miyazaki Yusuke, Nakayamada Shingo, Hanami Kentaro, Fukuyo Shunsuke, Kubo Satoshi, Yamaguchi Ayako, Inoue Yoshino, Todoroki Yasuyuki, Miyata Hiroko, Tanaka Hiroaki, Fujino Yoshihisa, Hirata Shintaro, Tanaka Yoshiya
Rheumatology (Oxford, England), May 2025, Reviewed, No invitation

Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Tanaka Yoshiya, Yamaguchi Ayako, Miyamoto Toshiaki, Tanimura Kazuhide, Iwai Hideyuki, Kaneko Yuko, Takeuchi Tsutomu, Amano Koichi, Iwamoto Naoki, Kawakami Atsushi, Murakami Miho, Nishimoto Norihiro, Atsumi Tatsuya, Sumida Takayuki, Ohmura Koichiro, Mimori Tsuneyo, Yamanaka Hisashi, Fujio Keishi, Fujino Yoshihisa, Saito Kazuyoshi, Nakano Kazuhisa, Hirata Shintaro, Nakayamada Shingo
Rheumatology (Oxford, England), Feb. 2022, Reviewed, No invitation

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.
Kanda Ryuichiro, Miyazaki Yusuke, Nakayamada Shingo, Fukuyo Shunsuke, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Satoh-Kanda Yurie, Ohkubo Naoaki, Todoroki Yasuyuki, Tanaka Hiroaki, Ueno Masanobu, Nagayasu Atsushi, Fujita Yuya, Aritomi Takafumi, Kusaka Katsuhide, Sakai Hidenori, Matsunaga Satsuki, Nohara Hirotsugu, Tanaka Yoshiya
Rheumatology and therapy, Mar. 2025, Reviewed, No invitation

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.
Nagayasu Atsushi, Miyazaki Yusuke, Sonomoto Koshiro, Kubo Satoshi, Miyagawa Ippei, Yamaguchi Ayako, Tanaka Hiroaki, Todoroki Yasuyuki, Ueno Masanobu, Aritomi Takafumi, Fujita Yuya, Sakai Hidenori, Suzuki Katsunori, Nakayamada Shingo, Tanaka Yoshiya
Rheumatology and therapy, Aug. 2025, Reviewed, No invitation

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.
Hirai Takuya, Ikeda Keigo, Fujishiro Maki, Tsushima Hiroshi, Hayakawa Kunihiro, Suzuki Satoshi, Yamaguchi Ayako, Nozawa Kazuhisa, Morimoto Shinji, Takasaki Yoshinari, Ogawa Hideoki, Takamori Kenji, Tamura Naoto, Sekigawa Iwao
Clinical rheumatology, Jan. 2017, Null, Null

赤沈、CRP
山口絢子, 田中良哉, Contributor
日本臨床社, Apr. 2022, Reviewed

自己免疫疾患患者におけるシングリックスの安全性と有効性に関する当院における報告
◎山口　絢子、田中　良哉
第38回日本日本臨床リウマチ学会総会, Nov. 2023, No invitation

JAK阻害薬不応関節リウマチ患者の特徴と最適な分子標的薬選択について～～FIRST registryより～
◎宮﨑佑介、中山田真吾、園本格士朗、田中宏明、久保智史、宮川一平、山口絢子、轟　泰幸、井上嘉乃、上野匡庸、田中良哉
第38回日本臨床リウマチ学会総会, Nov. 2023, No invitation

関節リウマチ分子標的治療薬の骨代謝へのクラスエフェクト; FIRST registry
◎大久保直紀、園本格士朗、中山田真吾、岩田慈、花見健太郎、福與俊介、山口絢子、河邊明男、田中健一、宮﨑佑介、井上嘉乃、岡田洋右、田中良哉
第40回骨代謝学会学術集会, 22 Jul. 2022, No invitation

全身性エリテマトーデス (SLE)の再燃を予測する末梢血免疫フェノタイプの検討 ～LOOPS/FLOW registry～
◎大久保直紀、中山田真吾、宮﨑佑介、田中宏明、藤田悠哉、園本格士朗、山口絢子、河邊明男、井上嘉乃、福與俊介、岩田慈、花見健太郎、田中良哉
第43回日本炎症・再生医学会, 06 Jul. 2022, No invitation

関節リウマチ（RA）におけるトファシチニブ(Tofa)による寛解および寛解維持に寄与する因子の検討 〜First registryより〜
◎井上嘉乃、中野和久、中山田真吾、岩田慈、花見健太郎、福與俊介、宮川一平、山口絢子、宮崎佑介、河邊明男、吉成紘子、田中良哉
第58回九州リウマチ学会, 07 Sep. 2019, No invitation

「FIRST registry におけるbDMARDs治療5年間の安全性と有効性」
◎福與俊介　中野和久　中山田真吾　岩田慈　山口絢子　宮川一平　宮﨑佑介　河邊明男　吉成紘子　田中良哉
第58回九州リウマチ学会, 07 Sep. 2019, No invitation

半月体形成は活動性ループス腎炎の52週および長期における予後不良因子である
◎名和田彩1,2、中野和久1、吉成紘子１、井上嘉乃1、大久保直紀1、佐藤友梨恵1、田中宏明1、轟泰幸1、宮田寛子1、上野匡庸1、永安敦1、有富貴史1、藤田悠哉1、神田龍一郎1、船田将史1、山口絢子１、吾妻妙子3、中塚敬輔４、名和田雅夫５、中山田真吾１、田中良哉1
第63回日本リウマチ学会, 15 Apr. 2019, No invitation

FIRST registryにおけるRA患者のbDMARDs治療成績:15年間の変化
◎福與俊介、中野和久、中山田真吾、岩田慈、花見健太郎、久保智史、宮川一平、山口絢子、宮﨑祐介、河邊明男、田中良哉
第63回日本リウマチ学会, 15 Apr. 2019, No invitation

１剤のbDMARDに治療不応性のRA患者における２剤目の有効性予測因子の検討　　〜First registryより〜
◎中野和久、中山田真吾、岩田慈、花見健太郎、福與俊介、久保智史、宮川一平、河邊明男、宮崎佑介、山口絢子、齋藤和義、田中良哉
第６３回日本リウマチ学会, 15 Apr. 2019, No invitation

Do HCQ and MMF improve treatment outcome in patients with SLE? ～from LOOPS registry～
◎大久保直紀、中野和久、岩田慈、花見健太郎、福與俊介、久保智史、宮川一平、山口絢子、河邊明男、宮崎佑介、中山田真吾、田中良哉
第６３回日本リウマチ学会, 15 Apr. 2019, No invitation

高齢者RAにおける生物学的製剤導入前スクリーニング検査の重要性 〜Fisrt Registryより〜
◎中野和久、田中宏明、宮田寛子、中山田真吾、岩田慈、福與俊介、久保智史、宮川一平、山口絢子、河邊明男、宮崎佑介、齋藤和義、田中良哉
第57回九州リウマチ学会, 09 Mar. 2019, No invitation

好酸球性多発血管炎性肉芽腫症（EGPA）と巨細胞性動脈炎（GCA）を合併した多発血管炎重複症候群の一例
◎有冨貴史、中野和久、河邊明男、今林慶祐、宮崎佑介、山口絢子、久保智史、福與俊介、花見健太郎、岩田慈、名和田彩、中山田真吾、田中良哉
第57回九州リウマチ学会, 09 Mar. 2019, No invitation

高齢RA患者ではどの生物学的製剤が長期継続率を改善させるか
◎河邊明男、中野和久、久保智史、中山田真吾、岩田慈、花見健太郎、福與俊介、宮川一平、山口絢子、宮﨑佑介、田中良哉
第56回九州リウマチ学会, 02 Sep. 2018, No invitation

HONORスタディからみる関節リウマチ寛解達成後、5年間の長期休薬の可能性
◎山口絢子、中山田真吾、中野和久、岩田慈、花見健太郎、福與俊介、久保智史、宮川一平、宮﨑佑介、河邊明男、平田信太郎、田中良哉
第56回九州リウマチ学会, 01 Sep. 2018, No invitation

関節リウマチ患者（RA）におけるTNF阻害剤アダリムマブとJAK阻害剤トファシチニブの骨代謝への影響の比較
◎福與俊介、中野和久、中山田真吾、岩田慈、花見健太郎、久保智史、宮川一平、山口絢子、宮﨑祐介、河邊明男、岡田洋右、齋藤和義、田中良哉
第4回日本骨免疫学会, 25 Jun. 2018, No invitation

TNF阻害剤無効RA患者における2剤目への切り替えに関する検討：FIRST registryより
◎中野和久、山口絢子、中山田真吾、岩田慈、花見健太郎、福與俊介、久保智史、宮川一平、玉城泰太郎、齋藤和義、田中良哉
第55回九州リウマチ学会, 03 Mar. 2018, No invitation

ステロイド大量療法導入SLE患者におけるヒドロキシクロロキンの糖尿病・脂質異常症の発症率に対する検討
◎玉城泰太郎、中野和久、大久保直紀、岩田慈、花見健太郎、福輿俊介、久保智史、宮川一平、山口絢子、中山田真吾、田中良哉
第55回九州リウマチ学会, 03 Mar. 2018, No invitation

FIRST registryにおける実臨床でのバイオ抗リウマチ薬の有効性と安全性
◎福與俊介、中野和久、中山田真吾、岩田慈、花見健太郎、久保智史、宮川一平、山口絢子、玉城泰太郎、齋藤和義、田中良哉
第55回九州リウマチ学会, 03 Mar. 2018, No invitation

当院における関節リウマチ（RA）患者に対する各生物学的製剤(bDMARDs)の継続率および中止理由
◎福與俊介、中野和久、中山田真吾、岩田慈、花見健太郎、久保智史、宮川一平、山口絢子、玉城泰太郎、齋藤和義、田中良哉
第54回九州リウマチ学会, 03 Sep. 2017, No invitation

MTX治療中にリンパ増殖性疾患（LPD）を発症したRA患者の特徴とIL-6受容体（IL-6R）の発現
◎中野和久、中山田真吾、岩田　慈、花見健太郎、福輿俊介、久保智史、宮川一平、山口絢子、玉城泰太郎、齋藤和義、田中　良哉
第54回九州リウマチ学会, 02 Sep. 2017, No invitation

生物学的製剤導入前検査で非結核性抗酸菌（NTM)が症が疑われたRA症例の検討～FIRST registryより～
◎田中宏明、中野和久、中山田真吾、岩田慈、福與俊介、宮川一平、山口絢子、玉城泰太郎、齋藤和義、田中良哉
第54回九州リウマチ学会, 02 Sep. 2017, No invitation

関節リウマチ治療における寛解休薬後の機能予後、FIRST registryより
◎山口絢子、井上嘉乃、大久保直紀、河邊明男、宮崎佑介、園本格士朗、福與俊介、花見健太郎、岩田慈、中山田真吾、田中良哉
第62回九州リウマチ学会, Sep. 2021, No invitation

数理モデルを用いた精密なRA分子標的治療薬選択-FIRSTregistry-
◎園本格士朗、中山田真吾、田中宏明、宮﨑佑介、岩田　慈、花見健太郎、福與俊介、山口絢子、河邊明男、大久保直紀、井上嘉乃、田中良哉
第63回九州リウマチ学会, Mar. 2022, No invitation

関節リウマチ患者におけるTNF阻害剤の骨粗鬆症に対する効果
◎中野和久1、齋藤和義1,2、久保智史1、中山田真吾1、岩田慈1、花見健太郎1、福輿俊介1、宮川一平1、山口絢子1、玉城泰太郎1、田中良哉1
第3回日本骨免疫学会, Jun. 2017, No invitation

FIRST registryにおけるRA患者のｂDMARDｓの治療成績の14年間の変化
◎福與俊介、中野和久、中山田真吾、岩田慈、花見健太郎、久保智史、宮川一平、山口絢子、宮﨑祐介、河邊明男、田中良哉
第56回九州リウマチ学会, 02 Sep. 2018, No invitation

高齢発症のSLE患者における臨床的特徴 ～LOOPS Registryより～
◎大久保直紀、中野和久、岩田慈、花見健太郎、福與俊介、久保智史、宮川一平、山口絢子、河邊明男、宮崎佑介、中山田真吾、田中良哉
第57回九州リウマチ学会, 09 Mar. 2019, No invitation

生物学的製剤導入前検査にて肺非結核性抗酸菌症(NTM)が疑われたRA症例の検討～FIRST registryより～
◎田中宏明、中野和久、中山田真吾、岩田慈、福與俊介、久保智史、宮川一平、山口絢子、玉城泰太郎、齋藤和義、田中良哉
第62回日本リウマチ学会総会・学術集会, 28 Apr. 2018, No invitation

MTX治療中にリンパ増殖性疾患（LPD）を発症したRA患者の特徴とIL-6受容体の発現
◎中野和久、中山田真吾、名和田彩、岩田慈、花見健太郎、福輿俊介、久保智史、宮川一平、山口絢子、玉城泰太郎、齋藤和義、田中良哉
第62回日本リウマチ学会総会・学術集会, 26 Apr. 2018, No invitation

The association of serum biomarkers with joint destruction in patients with rheumatoid arthritis treated by certolizumab pegol, from the FIRST registry
◎Atsushi Nagayasu, Yusuke Miyazaki, Shingo Nakayamada, Yoshino Inoue, Yasuyuki Todoroki, Hiroko Miyata, Ayako Yamaguchi, Hiroaki Tanaka, Satoshi Kubo, Koshiro Sonomoto, Kentaro Hanami, Shunsuke Fukuyo, Yoshiya Tanaka
第67回日本リウマチ学会総会・学術集会, Apr. 2023, No invitation

Safety and efficacy of the adjuvanted recombinant zoster vaccine in patients with rheumatic disease: a prospective cohort study (Zoster-J)
◎Ayako Yamaguchi, Shingo Nakayamada, Kentaro Hanami, Koshiro Sonomoto, Yusuke Miyazaki, Hiroaki Tanaka, Yasuyuki Todoroki, Hiroko Miyata, Yoshiya Tanaka
第67回日本リウマチ学会総会・学術集会, Apr. 2023, No invitation

Predictive factors of efficacy of first-line CTLA4-Ig in patients with rheumatoid arthritis (RA) and high disease activity - FIRST registry-
◎Hiroki kobayashi,Yusuke Miyazaki, Koshiro Sonomoto, Shingo Nakayamada, Yoshino Inoue, Yasuyuki Todoroki, Hiroko Miyata, Ayako Yamaguchi, Hiroaki Tanaka, Satoshi Kubo, Kentaro Hanami, Shunsuke Fukuyo, Yoshiya Tanaka
第67回日本リウマチ学会総会・学術集会, Apr. 2023, No invitation

Treatment strategy in patients with rheumatoid arthritis and inadequate response to Janus kinase inhibitors from the FIRST registry
◎Yusuke Miyazaki, Shingo Nakayamada, Koshiro Sonomoto, Hiroaki Tanaka, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ayako Yamaguchi, Yasuyuki Todoroki, Miyata Hiroko, Yoshiya Tanaka
第67回日本リウマチ学会総会・学術集会, Apr. 2023, No invitation

Relationship between the effect of belimumab on immunophenotype and the discontinuation of glucocorticoids in patients with SLE in the maintenance phase: LOOPS registry, FLOW study
◎Yusuke Miyazaki,Shingo Nakayamada, Satoshi Kubo, Koshiro Sonomoto, Hiroaki Tanaka, Kentaro hanami, Shunsuke Fukuyo, Ayako Yamaguchi, Yasuyuki Todoroki, Hiroko Miyata, Yoshiya Tanaka
第67回日本リウマチ学会総会・学術集会, Apr. 2023, No invitation

Safety profile of the adjuvanted recombinant zoster vaccine: Zoster-J is a single center’s experience with rheumatoid arthritis patients
◎Ayako Yamaguchi, Shingo Nakayamada, Koshiro Sonomoto, Yusuke Miyazaki, Akio Kawabe, Hiroko Korekoda, Naoaki Okubo, Yoshino Inoue, Hiroko Miyata, Atsushi Nagayasu, Rhuichiro Kanda, Yuya Fujita, Shunsuke Fukuyo, Shigeru Iwata, Kentaro Hanami,Yoshiya Tanaka
第66回日本リウマチ学会総会・学術集会, 26 Apr. 2022, No invitation

Safety of biologic disease-modifying antirheumatic drugs and remission induction strategy in elderly patients with rheumatoid arthritis from the FIRST registry
◎Akio Kawabe, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Satoshi Kubo, Ayako Yamaguchi, Yusuke Miyazaki, Hiroko Yoshinari, Yoshiya Tanaka
第64回日本リウマチ学会総会・学術集会, Aug. 2020, No invitation

15-year risk management for biologic and targeted synthetic DMARDs for treatment of RA -FIRST registry-
◎Shunsuke Fukuyo, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Ayako Yamaguchi, Ippei Miyagawa, Yusuke Miyazaki, Akio Kawabe, Yoshiya Tanaka
第64回日本リウマチ学会総会・学術集会, Aug. 2020, No invitation

Drug survival rates and reasons for discontinuation in elderly patients with rheumatoid arthritis(RA) treated with biologic disease-modifying antireumatic drugs(bDMARDs)
◎Akio Kawabe , Kazuhisa Nakano , Shingo Nakayamada , Shigeru Iwata , Kentaro Hanami , Shunsuke Fukuyo , Satoshi Kubo , Ippei　Miyagawa , Ayako Yamaguchi , Yasutaro Tamaki , Yoshiya Tanaka
第62回日本リウマチ学会総会・学術集会, 26 Apr. 2018, No invitation

Long term outcomes after discontinuation of adalimumab in rheumatoid arthritis patients with achieving remission:5-year data of the HONOR study
◎Ayako Yamagauchi, Shintaro Hirata, Satoshi Kubo, Ippei Miyagawa, Shunsuke Fukuyo, Kentaro Hanami, Shigeru Iwata, Kazuhisa Nakano, Shingo Nakayamada, Yoshiya Tanaka
第62回日本リウマチ学会総会・学術集会, 26 Apr. 2018, No invitation

Comparison of the efficacy of biologic monotherapy using propensity score matching in RA
◎Kazuyoshi Saito, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Shigeru Iwata, Kentaro Hanami, Ippei Miyagawa, Shunsuke Fukuyo, Ayako Yamaguchi, Masao Nawata, Atsushi Nagayasu, Yoshiya Tanaka
第62回日本リウマチ学会総会・学術集会, Apr. 2018, No invitation

保存条件による25(OH)ビタミンD値の安定性
◎比嘉　幸枝, 大谷　恭子, 田中　佳奈子, 安達　浩子, 中園　朱美, 山口　絢子, 本田　雅久, 竹内　正明
第58回日本臨床化学会年次学術集会, 24 Aug. 2018, No invitation

超音波検査が有用であった原発性副甲状腺機能亢進症の1例
◎西野 達士, 中園 朱実, 赤迫 義満, 池田 直美, 磯辺 洋子, 津留 孝浩, 浪崎 秀洋, 吉村 汐里, 本田 雅久, 大谷 恭子, 山口 絢子, 島尻 正平, 竹内 正明
第62回日本臨床検査医学会九州地方会, 04 Mar. 2017, No invitation